Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

European Journal of Pharmacology

Volumn 535, Issue 1-3, 2006, Pages 135-144

  Cosi, Cristina ^a   Carilla Durand, Elisabeth ^a   Assié, Marie Bernadette ^a   Ormiere, Anne Marie ^a   Maraval, Mireille ^a   Leduc, Nathalie ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

(Rat); Antipsychotics; Dopamine D2 receptor; Partial agonist; Prolactin; Sf9 cell

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DOPAMINE 2 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; HALOPERIDOL; NEUROLEPTIC AGENT; RACLOPRIDE; SLV 313; SSR 181507; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN BINDING; RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOXAZOLES; BINDING, COMPETITIVE; CELL LINE; CLOZAPINE; DIOXANES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HALOPERIDOL; HUMANS; MALE; PIPERAZINES; PROLACTIN; QUINOLONES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SEROTONIN AGONISTS; SPODOPTERA; SULFUR RADIOISOTOPES; TROPANES;

EID: 33645451501     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.01.051     Document Type: Article

References (43)

1. N.-E. Andén, M. Grabowska-Andén, and B. Liljenberg On the presence of autoreceptors on dopamine neurons in different brain regions J. Neural Transm. 60 1983 129 137
2. 1A agonist properties. Neuropsychopharmacology (published online: 19 October 2005, doi:10.1038/sj.npp.1300940).
3. N. Ben-Jonathan Dopamine: a prolactin-inhibiting hormone Endocr. Rev. 6 1985 564 589
4. D.K. Burris, F.T. Molski, C. XU, E. Ryan, K. Tottoro, T. Kikuchi, D.F. Yocca, and B.P. Molinoff Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J. Pharmacol. Exp. Ther. 302 2002 381 389
5. D. Clark, S. Hjorth, and A. Carlsson Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: I. Review of the evidence J. Neural Transm. 62 1985 1 52
6. 1A receptor agonist: I. Neurochemical and electrophysiological profile Neuropsychopharmacology 28 2003 2064 2076
7. T.M. Compton, and H.A. Miller Antipsychotic-induced hyperprolactinemia and sexual dysfunction Psychopharmacol. Bull. 36 2002 144 164
8. B. Demarest, and K.E. Moore Comparison of dopamine synthesis regulation in the terminals of nigrostratal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons J. Neural Transm. 46 1979 263 277
9. 1A receptor agonist: II. Behavioral profile predictive of an atypical antipsychotic activity Neuropsychopharmacology 28 2003 1889 1902
10. 11C-raclopride by means of position emission tomography Col. Eur. Neuropsychopharmacol. 10 2000 S294
11. A. Di Sciullo, M.T. Bliet-Pajot, F. Mounier, C. Oliver, B. Schmidt, and C. Kordon Changes in anterior pituitary hormone levels after serotonin1A receptor stimulation Endocrinology 127 1990 567 572
12. B. Drukarch, and J.C. Stoof D2 dopamine autoreceptor selective drugs: do they really exist? Life Sci. 47 1990 361 376
13. P. Falardeau Functional distinctions of dopamine D2Long and D2Short receptors H.B. Niznik Dopamine Receptors and Transporters: Pharmacology, Structure and Function 1994 Marcel Dekker, Inc New York, NY 323 342
14. 1A receptor agonist: in vivo and in vivo neuropharmacology Eur. Col. Neuropsychopharmacol. 12 2002 S227
15. G.A. Gudelsky, J.F. Nash, S.A. Berry, and H.Y. Meltzer Basic biology of clozapine: electrophysiological and neuroendocrinological studies Psychopharmacology 99 1989 S13 S17
16. P.M. Haddam, and A. Wieck Antipsychotics-induced hyperprolactinemia: mechanisms, clinical features and management Drugs 64 2004 2291 2314
17. N.R. Hanley, and L.D. Van de Kar Serotonin and the neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis in health and disease Vitam. Horm. 66 2003 189 255
18. T. Hirose, Y. Uwahodo, S. Yamada, T. Miwa, T. Kikuchi, H. Kitagawa, K.D. Burris, C.A. Altar, and T. Nabeshima Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile J. Psychopharmacol. 18 2004 375 383
19. T. Inoue, M. Domae, K. Yamada, and T. Furukawa Effects of the novel antipsychotic agaent 7-{4-[-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4- dihydro-2(1 H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland J. Pharmacol. Exp. Ther. 277 1995 137 143
20. (1A) receptor activation in attenuation of catalepsy induction in rats Neuropharmacology 49 2005 135 143
21. J.K.P. Knight, A.T. Pfeifer, and A.T. Grigliatti A functional assay for G-protein-coupled receptors using stably transformed insect tissue culture cell lines Anal. Biochem. 320 2003 88 103
22. P.C. Lawler, C. Prioleau, M.M. Lewis, C. Mak, D. Jiang, A.J. Schetz, M.A. Gonzalez, R.D. Sibley, and B.R. Mailman Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 20 1999 612 627
23. D.F. Levison Pharmacologic treatment of schizophrenia Clin. Ther. 13 1991 326 352
24. R.A. Maurer Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP Nature 294 1981 94 97
25. 1A agonist: efficacy in antipsychotic models with reduced propensity for EPS symptoms Program No. 349.1 Abstract Viewer/Itinerary Planner 2004 Society for Neurosciences Washington, DC Online
26. H.Y. Meltzer The mechanism of action of novel antipsychotic drugs Schizophr. Bull. 17 1991 263 287
27. H.Y. Meltzer, S. Daniels, and V.S. Fang Clozapine increases rat serum prolactin levels Life Sci. 17 1975 339 342
28. H.Y. Meltzer, M. Simonovic, V.S. Fang, and G.A. Gudelsky Effects of buspirone on rat plasma prolactin levels and striatal dopamine turnover Psychopharmacology 78 1982 49 53
29. H.Y. Meltzer, R. Fleming, and A. Robertson The effects of buspirone on prolactin and growth hormone secretion in man Arch. Gen. Psychiatry 40 1983 1099 1102
30. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia Int. J. Neuropsychopharmacol. 11 2005 1 16
31. 3H]dopamine in the rat basal hypothalamus and neurointermediate lobe of the pituitary gland Brain Res. 413 1987 205 212
32. P. Seeman, T. Lee, M. Chau-Wong, and K. Wong Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 1976 717 719
33. A.D. Shapiro, S. Renock, E. Arrington, A.L. Chiodo, L.-X. Liu, R.D. Sibley, L.B. Roth, and R. Mailman Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
34. P. Sokoloff, B. Giros, M.-P. Martres, M.-L. Bouthenet, and J.-C. Schwartz Molecular cloning and characterization of a novel dopamine receptor (D3) as a target of neuroleptics Nature (London) 347 1990 146 151
35. 1A receptor mechanisms in vivo Naunyn-Schmiedeberg's Arch. Pharmacol. 371 2005 18 26
36. Y. Tadori, T. Miwa, K. Tottori, D.K. Burris, A. Stark, T. Mori, and T. Kikuchi Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic Eur. J. Pharmacol. 515 2005 10 19
37. J.R. Tallarida, and B.R. Murray Manual of Pharmacological Calculations with Computer Programs second ed. 1987 Springer-Verlag New York
38. M. Toru, S. Miura, and Y. Kudo Clinical experience of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients Neuropsychopharmacology 10 1994 122S
39. 2A receptors stimulate ACTH, corticosterone, oxitocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells J. Neurosci. 21 2001 3572 3579
40. H.H.M. Van Tol, J.R. Bunzow, H.-C. Guan, R.K. Sunahara, P. Seeman, H.B. Niznik, and O. Civitelli Cloning of the gene of a human D4 receptor with high affinity for the antipsychotic clozapine Nature (London) 350 1991 610 614
41. B.J. Van Vliet, E. Ronken, M. Tulp, R. Feenstra, C.G Kruse, and S.K. Long DU 127090: a highly potent, atypical dopamine receptor ligand-high potency but low efficacy at dopamine D2 receptors in vitro Eur. Col. Neuropsychopharmacol. 10 2000 S294
42. A. Vicentic, Q. Li, G. Battaglia, and L.D. Van de Kar WAY 100635 inhibits 8-OH-DPAT-stimulated oxytocine, ACTH and corticosterone, but not prolactin secretion Eur. J. Pharmacol. 346 1998 261 266
43. 2A receptors in hypothalamic paraventricular nucleus mediate neuroendocrine response to (-)DOI J. Neurosci. 22 2001 9635 9642